Louise Chen

How To Earn $500 From Pfizer Stock With Shares Trading At 52-Week Low
Eli Lilly Analysts Bump Up Forecasts On Q2 Print: Mounjaro, Alzheimer's Franchise Key To Future Growth
Pfizer's Late-Stage COVID-19 Vaccine Data In Adolescents Reinforces Bull Case, Analyst Says
Eli Lilly Analysts Bump Up Forecasts On Q2 Print: Mounjaro, Alzheimer's Franchise Key To Future Growth
Pfizer's Late-Stage COVID-19 Vaccine Data In Adolescents Reinforces Bull Case, Analyst Says
Pfizer-BioNTech Plan Vaccine Emergency Use Filing Within Days After Final Analysis Confirm Efficacy, Safety
A Pfizer Analyst's 3 Possible Coronavirus Vaccine Readout Scenarios

Louise Chen Recent News

4 Takeaways On Pfizer's Latest Coronavirus Data
The data shows more positives about Pfizer’s (NYSE: PFE) coronavirus vaccine candidate and remains in-line with its German partner BioNTech’s (NASDAQ: BNTX) study, according to Cantor Fitzgerald Secur
Amarin Analysts Say Vascepa Patent Settlement Not A Stock Mover, With 'Little Readthrough For Pending Patent Appeal'
Amarin Corporation plc (NASDAQ: AMRN) announced late Tuesday a settlement agreement with Apotex for resolving a patent lawsuit regarding a generic version of Amarin's drug Vascepa. 
Pfizer Analyst Takes Stock Of Negative Breast Cancer Data, Pharma Giant's 2025 Goals
Pfizer Inc.
Merck's Coronavirus Plan Of Attack: 2 Partnerships, M&A Deal Aimed At Treatment, Vaccine Development
Merck & Co., Inc. (NYSE: MRK) announced a trio of initiatives Tuesday to combat the coronavirus pandemic. 
Merck Analysts Focus On Fundamentals, Keytruda Strength Following Guidance Cut
Merck & Co., Inc. (NYSE: MRK) shares came under pressure in Tuesday's session after the pharma company lowered its full-year guidance.
Amarin Analysts React To Vascepa Patent Loss, See Small Chance Of Overturning Judgment
Merck To Spin Off Slow-Growing Women's Health, Legacy, Biosimilars Businesses: What You Need to Know
After Amarin Snags Vascepa Label Expansion, Analyst Says Biopharma An Attractive M&A Target
Analyst: Peak Sales Potential Of Amarin's Vascepa Underappreciated
Amarin Shares Climb Following In-Line Review Of Fish Oil Pill By FDA Staffers
Mylan's Disappointing Outlook Rattles Analysts, Investors
Cantor Fitzgerald Names 8 Upcoming Biotech Catalysts
Analyst: Why The Sucampo Deal Is A Smart Move For Mallinckrodt
Valeant Investors: Cantor Says It's Time To Stop Waiting For The Other Shoe To Drop
UPDATE: Guggenheim Securities Reiterates on Cadence Pharmaceuticals as Earnings Visibility for Ofirmev Improves
Johnson & Johnson (JNJ) Woes Benefit Perrigo (PRGO)
Teva Pharmaceuticals Industries Ltd. (TEVA) Quarterly EPS Estimates For 2010 Revised